Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.685 USD | -2.88% | -2.03% | -44.02% |
May. 10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Financials (USD)
Sales 2024 * | 7.98M | Sales 2025 * | 64.05M | Capitalization | 43.15M |
---|---|---|---|---|---|
Net income 2024 * | -7M | Net income 2025 * | 44M | EV / Sales 2024 * | 5.41 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.67 x |
P/E ratio 2024 * |
-5.91
x | P/E ratio 2025 * |
0.94
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.04% |
Latest transcript on Ocuphire Pharma, Inc.
1 day | -2.88% | ||
1 week | -2.03% | ||
Current month | +6.31% | ||
1 month | +0.90% | ||
3 months | -35.93% | ||
6 months | -42.49% | ||
Current year | -44.02% |
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | Oct. 31 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | Feb. 13 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 20-10-31 |
James Manuso
BRD | Director/Board Member | 75 | 18-12-31 |
Susan Benton
BRD | Director/Board Member | 59 | 20-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.685 | -2.88% | 114,524 |
24-05-16 | 1.735 | +0.29% | 66,737 |
24-05-15 | 1.73 | +1.76% | 130,344 |
24-05-14 | 1.7 | +1.19% | 84,910 |
24-05-13 | 1.68 | -2.33% | 214,820 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.02% | 43.15M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- OCUP Stock